Shares of Tilray Inc (NASDAQ:TLRY - Get Free Report) were down 4.6% during trading on Tuesday . The stock traded as low as $0.64 and last traded at $0.65. Approximately 12,968,518 shares changed hands during trading, a decline of 71% from the average daily volume of 45,452,867 shares. The stock had previously closed at $0.68.
Analyst Upgrades and Downgrades
Separately, Canaccord Genuity Group lifted their price target on shares of Tilray from $2.00 to $3.00 and gave the stock a "buy" rating in a research note on Monday, January 13th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $2.70.
Get Our Latest Stock Analysis on TLRY
Tilray Trading Up 2.6 %
The company has a debt-to-equity ratio of 0.10, a current ratio of 2.54 and a quick ratio of 1.58. The firm's 50 day moving average is $1.05 and its 200 day moving average is $1.38. The company has a market capitalization of $650.45 million, a PE ratio of -2.31 and a beta of 2.13.
Tilray (NASDAQ:TLRY - Get Free Report) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.07). The company had revenue of $210.90 million during the quarter, compared to the consensus estimate of $216.34 million. Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. The company's quarterly revenue was up 8.7% compared to the same quarter last year. As a group, equities analysts predict that Tilray Inc will post -0.2 EPS for the current year.
Institutional Trading of Tilray
A number of hedge funds have recently modified their holdings of TLRY. BNP Paribas Financial Markets boosted its holdings in shares of Tilray by 1,314.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,819,494 shares of the company's stock valued at $3,202,000 after buying an additional 1,690,827 shares in the last quarter. Tidal Investments LLC boosted its holdings in shares of Tilray by 9.2% during the 4th quarter. Tidal Investments LLC now owns 10,595,264 shares of the company's stock valued at $14,092,000 after buying an additional 889,086 shares in the last quarter. Quinn Opportunity Partners LLC boosted its holdings in shares of Tilray by 108.0% during the 4th quarter. Quinn Opportunity Partners LLC now owns 1,618,080 shares of the company's stock valued at $2,152,000 after buying an additional 840,000 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Tilray during the 4th quarter valued at $1,029,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Tilray by 54.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,172,935 shares of the company's stock valued at $2,890,000 after buying an additional 769,569 shares in the last quarter. Institutional investors own 9.35% of the company's stock.
About Tilray
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
See Also
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
